Company Filing History:
Years Active: 2018
Title: Innovations in Lipid Management by Ting-Yun Shen
Introduction
Ting-Yun Shen is a notable inventor based in Taichung, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the area of lipid management. His work focuses on developing innovative solutions for treating hyperlipidemia, a condition characterized by elevated levels of lipids in the blood.
Latest Patents
Ting-Yun Shen holds a patent for the use of GMNL-263 in decreasing blood lipid levels. This compound, identified by accession No.: CCTCC M 209263, specifically inhibits gene expression related to pro-inflammatory factors and lipid synthesis. Additionally, it promotes gene expression related to cholesterol metabolism. The application of GMNL-263 is aimed at producing a composition that effectively decreases blood lipid levels, thereby providing a treatment option for hyperlipidemia.
Career Highlights
Ting-Yun Shen is associated with Genmont Biotech Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on public health, particularly in managing cholesterol levels and improving cardiovascular health.
Collaborations
Ting-Yun Shen collaborates with esteemed colleagues, including Yi-Hsing Chen and Ya-Hui Chen. Their combined expertise contributes to the innovative research and development initiatives at Genmont Biotech Inc.
Conclusion
Ting-Yun Shen's contributions to biotechnology, particularly in lipid management, highlight the importance of innovation in addressing health challenges. His patent on GMNL-263 represents a significant step forward in the treatment of hyperlipidemia.